SLC5A2 and malignant colon neoplasm: Dual therapy was associated with a lower risk of colon cancer compared with SGLT-2 inhibitor alone (HR 0.786, 95% CI 0.671–0.919; P = 0.003), representing a 21% relative risk reduction (NNT = 490 over 5 years).